Drug discovery and development services from idea to IND
Your transatlantic drug discovery and development partner – helping you to realize the full value of your transformative therapies from inception to IND.
Your transatlantic partner for discovery and development
Our connected teams across Europe and the US link chemistry, biology, ADME-tox and CMC expertise under one accountable approach, so your progress is clear, continuous and fast.
600+ scientists, 1 team
Experience chemists, biologists and development specialists working in a single integrated unit
9 global sites
Connected facilities across Europe and North America for easy collaboration and consistent quality
1 connected partner
Discovery through IND under 1 program lead, reducing handoff, duplication and delay
Relied on by biopharma worldwide
From fast-moving biotechs to global pharma, teams repeatedly choose Symeres knowing we excel at three things:
You’ll always know what’s happening, and why
We adapt quickly when data or priorities change
Every result, every decision, is backed by experience
Your drug discovery and development partner
Integrated drug discovery and development services
We provide flexible support – from standalone studies to fully integrated programs – designed to keep your data connected, your communication clear, and your project on track.
Drug discovery
Chemistry
Medicinal, computational, synthetic, and specialty chemistry for design, synthesis, and optimization of small molecules. Capabilities include SAR development, structure-based design, parallel synthesis, and route optimization.
ADME
In vitro and in vivo ADME studies to define pharmacokinetic and metabolic profiles. Late-stage ADME support links directly with solid-state and formulation groups to proactively anticipate developability risks.
Biology
Assays for target validation, potency, biomarkers and mechanism of action studies. Capabilities include in vitro enzymatic and cell-based systems, supported by bioinformatics
Drug delivery
Lipid and polymer chemistry to improve solubility, stability, and targeted delivery of small molecules, nucleic acid therapeutics and other modalities.
Drug development
Preclinical
Support from candidate selection through IND/IMPD. Reduce risk, generate regulatory-ready data and documentation, and streamline your progression into the clinic.
CMC and beyond
Scalable development and GMP manufacturing capabilities ensure your molecule is ready for clinical and commercial success.
ADME-Tox
Comprehensive ADME and toxicology testing to proactively identify risks early and support smarter, faster decision-making throughout early-stage drug development.
What do our partners say?
“Through our dedicated FTE resource at Symeres we have achieved remarkable results, not only by developing a new “aspirational” synthetic route but also by significantly improving the current one to deliver a sustainable route for commercial production and giving us two options for late development.”
Associate Director
Large pharma, Europe
“They’ve always met or exceeded my expectations - that’s why I continue to come back, company after company, year after year.”
Allen Horhota, Vice-President Platform & Delivery
Seamless Therapeutics
“A sign that things are going well - we keep coming to you. We’ve given Symeres five or six different projects already. That’s almost unheard of for us.“
Senior Director, Manufacturing
Top 10 global pharma
“We are developing the most complex molecule that is built at this time in the world…We work with a lot of CROs, also chemistry CROs, and so far Symeres has done the best job with respect to transparency and also to troubleshoot the problems and find a solution. Over the years we have been really impressed with the work that Symeres has done.”
Founder
Biotech
“I would like to extend my thanks for the excellent work Symeres has done in synthesizing the API for Part 1 of our project. Your communication throughout the process was outstanding, and the sense of urgency with which you operated allowed us to complete this phase promptly and efficiently.”
Leader
Large biotech
“The team is making short work of these targets, so we will have to start thinking of some additional targets!”
Director
Biotech
“The progression was really phenomenal. I am truly impressed. There is a world of difference between you and other CROs.”
Start-up Founder
Biotech
“If the compound can be made, Symeres will undoubtedly find out a good way to make it.”
Dooyoung Jung, CEO
Pinotbio
“We’ve been with them…over 10 years. The cost, the flexibility - the value is just so strong. That’s why we’ve stuck with them.”
Senior Director, CMC
Biotech
Drug discovery and development success stories
Every program is unique, but the goal is always the same: reliable progress.
Our integrated teams have helped clients overcome tough chemistry, unpredictable biology, and scale-up challenges to deliver clinical-ready candidates.
Latest news from Symeres
Symeres earns first SBTi approval as part of long-term sustainability journey
